Elevated expression of COX-2 and increased levels of PGE 2 are found in numerous cancers and are associated with tumour development and progression. Although epidemiological, clinical and preclinical studies have shown that the inhibition of PGE 2 synthesis through the use of either non-steroidal anti-inflammatory drugs (NSAIDs) or specific COX-2 inhibitors (COXibs) has the potential to prevent and treat malignant disease, toxicities due to inhibition of COX-2 have limited their use. Thus, there is an urgent need for the development of strategies whereby COX-2 activity may be reduced without inducing any side effects. The biological effects of PGE 2 are mediated by signalling through four distinct E-type prostanoid (EP) receptors -EP 1 , EP 2 , EP 3 and EP 4 . In recent years, extensive effort has gone into elucidating the function of PGE 2 and the EP receptors in health and disease, with the goal of creating selective inhibitors as a means of therapy. In this review, we focus on PGE 2 , and in particular on the role of the individual EP receptors and their signalling pathways in neoplastic disease. As knowledge concerning the role of the EP receptors in cancer grows, so does the potential for exploiting the EP receptors as therapeutic targets for the treatment of cancer and metastatic disease.
Introduction
Inflammation has been established in recent years as playing a major role in cancer, with cancer-promoting inflammation an enabling characteristic underlying many, if not all, of the six hallmarks of cancer (Hanahan and Weinberg, 2011) . In some cancers, the inflammatory conditions precede the development of malignancy, for example, ulcerative colitis is a major risk factor for colon cancer (Gupta et al., 2007) . Alternatively, oncogenic mutations can drive tumour-promoting inflammation in tumours that are epidemiologically unrelated to overt inflammatory conditions (Del Prete et al., 2011) . One key inflammatory mediator deregulated in many cancers is the COX enzyme, COX-2 (Janakiram and Rao, 2014) . COX-2 expression has been shown in many cancers to be inversely associated with patient survival (Gallo et al., 2002; Peng et al., 2013; Sicking et al., 2014) , with epidemiological studies suggesting that regular aspirin use decreases colorectal cancer incidence and mortality through the inhibition of COX-2 (Chan et al., 2009) . Thus, drugs that target COX-2 may have chemopreventative or chemotherapeutic functions. Although drugs that target the COX enzymes have entered the clinic, albeit for different diseases, inhibition of COX-2 using either non-steroidal anti-inflammatory drugs (NSAIDs) or specific COX-2 inhibitors (COXibs) is associated with various side effects including gastric ulceration and myocardial infarction (Ranger, 2014) . Such toxicities have limited their clinical applications.
Dysregulation of COX-2 leads to elevated levels of its principle metabolic product, PGE 2 . PGE 2 is produced from arachidonic acid through the actions of COX enzymes and PGE synthases ( Figure 1 ) and is catabolized in turn to the inactive 15-keto-PGE 2 by the enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH also known as HPGD) (Tai et al., 2002) . Elevated levels of PGE 2 have been found in numerous cancers, with PGE 2 shown to be responsible for many of the pro-tumorigenic effects seen following COX-2 dysregulation (Wu et al., 2010) . However, PGE 2 is not the only product of COX-2, with the toxicities associated with COX-2 inhibition proposed to be due to the concurrent inhibition of prostacyclin (PGI 2 ) (Cannon and Cannon, 2012) , resulting in an imbalance in the levels of PGI 2 and thromboxanes in the body, increasing cardiovascular risk.
PGE 2 signals through four pharmacologically distinct, Gprotein coupled plasma membrane receptors, EP 1 , EP 2 , EP 3 and EP 4 , which can each activate different downstream signalling pathways (Sugimoto and Narumiya, 2007) . Differential suppression of PGE 2 biological activity could thus potentially retain the anticancer benefits of COX-2 inhibition, whilst circumventing the adverse side effects. Numerous studies in recent years have focused on identifying the specific EP receptors and signalling pathways that mediate 
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the pleiotropic activities of PGE 2 in an attempt to identify the receptor(s) that represents the best target(s) for anticancer therapy. In this review, the emphasis is on outlining recent findings on the signalling pathways activated by the individual EP receptors and the potential role of the EP receptor antagonists in malignancy.
The EP receptors
Following synthesis, PGE 2 exits the cell where it acts in either an autocrine or paracrine manner via one of its four receptors (Sugimoto and Narumiya, 2007) . Interactions between PGE 2 and its receptors are thought to be dependent on tissue/cell type and location, specific receptor expression and variation in binding affinities (Narumiya et al., 1999) . The EP 3 and EP 4 receptors represent high-affinity receptors, whereas activation of EP 1 and EP 2 receptors requires significantly higher levels of PGE 2 . These variables can thus lead to differential receptor activation, providing PGE 2 with the ability to mediate highly varied effects on cell biology in many different tissue types and disease states. The EP 1 receptor is coupled to the Gα q protein subunit that activates phosphoinositide-PLC (Figure 2A ). Activation of PLC ultimately leads to an increase in intracellular Ca 2+ and activation of PKC, inducing gene transcription through the activation of nuclear factor of activated T cells (NFAT), nuclear factor-kappaB (NFκB) and the MAPK pathways (Sugimoto and Narumiya, 2007) .
Both the EP 2 and EP 4 receptors are linked to G-stimulatory (Gα s ) proteins and activate adenylate cyclase, increasing cAMP levels in the cell, which results in the activation of PKA ( Figure 2B and C). PKA directly phosphorylates and activates transcription factors such as the cAMP-responsive element binding protein (CREB). Both receptors can also activate the GSK3β/β-catenin pathway, which in turn increases the transcription of many genes implicated in cancer, such as c-myc, cyclin D1 and VEGF. However, activation of the GSK3/β-catenin pathway by the EP 2 receptor occurs primarily through the activation of PKA, whereas the activation of the T cell factor (TCF)-β-catenin signalling by the EP 4 receptor primarily involves the activation of the PI3K/Akt pathway (Fujino et al., 2002) .
The EP 3 receptor is unique in that it exists as alternative spliced variants, characterized by differences in the cytoplasmic C-terminal tail (Namba et al., 1993) . As a result, the EP 3 receptor is capable of coupling with a number of G-protein subunits including G i , G s and G 13 , and is thus capable of stimulating or inhibiting cAMP (by stimulating or inhibiting adenylate cyclase), as well as stimulating Ca 2+ mobilization, possibly via PLC ( Figure 2D ). The major EP 3 splice variant though is thought to be coupled to an inhibitory (G i ) protein, and hence the major outcome of PGE 2 -EP 3 receptor signalling is inhibition of adenylate cyclase and activation of the Ras/ Raf and MAPK signalling pathway (Woodward et al., 2011) .
Crosstalk with other signalling pathways
Numerous studies have recently shown that significant crosstalk exists between the EP receptors, in particular EP 1 , EP 2 (Sales et al., 2004) and EP 4 (Oshima et al., 2011) , and the EGF receptor (EGFR) signalling pathway, adding a further level of complexity to the EP receptor signalling pathways (Figure 3 ). The EGFR is located on the cell surface and is activated by binding of its specific ligands, including EGF and TGFα (Jorissen et al., 2003) . Transactivation of the EGFR by the EP receptors involves the activation of cSrc, which either activates EGFR directly by phosphorylation or indirectly by inducing a matrix metalloproteinase activity that releases membrane-bound TGFα (Pai et al., 2002) . Activation of the EGFR leads to the activation of several signal transduction cascades, principally the MAPK, PI3K/Akt, STATand PLC signalling pathways, resulting in cell proliferation, differentiation, migration and survival. The EGFR has also been shown to be involved in the pathogenesis and progression of numerous tumour types. Aberrant activation of the EGFR promotes uncontrolled cell proliferation and metastasis (Normanno et al., 2006) , with EGFR inhibitors approved for the treatment of non-small-cell, pancreatic, breast and colon cancer (Wykosky et al., 2011) . Despite the dramatic response seen to these inhibitors, most patients ultimately become resistant to the therapy (Wykosky et al., 2011) . The ability of PGE 2 , acting through the EP receptors to transactivate the EGFR, may be responsible for the Figure 1 Prostaglandin E 2 biosynthesis. Following its release from cellular membranes through the actions of phospholipase A 2 family members, arachidonic acid is converted to PGH 2 through the activity of the COX enzymes. COX-1 is constitutively expressed at basal levels in many cells, generating low levels of PGs that are cytoprotective and maintain homeostasis. In contrast, COX-2 is normally absent from most cells but is induced in response to a variety of stimuli including growth factors and cytokines. PGH 2 is rapidly converted to PGE 2 by one of three PGE 2 synthases -cPGES, mPGES-1 or mPGES-2. PGE 2 is degraded, in turn, into 15-keto PGE 2 by 15-PGDH. PGE 2 signals through four GPCRs, EP 1 , EP 2 , EP 3 and EP 4 . NSAIDs and COXibs, which block the activity of the COX enzymes, and inhibitors of the PGE 2 synthases can potentially suppress the pro-tumorigenic effects of PGE 2 by reducing its synthesis. Alternatively, targeting the individual EP receptors may suppress the activity of PGE 2 .
development of resistance in some cancer patients. However, clinical trials combining COX-2 specific inhibitors, including celecoxib and aproxicoxib, with EGFR inhibitors, such as erlotinib, have showed limited success, and in some patients, increased toxicity (Csiki et al., 2005; Gitlitz et al., 2014) .
Studies such as these underscore the importance of improving our understanding of tumour biology to individualize cancer therapies and the identification of novel biomarkers to predict patient cohorts most likely to respond to therapy. Moreover, given that PGE 2 acts through multiple receptors, characterising the role of the individual receptors in carcinogenesis may identify a receptor, or combination of receptors, which offers a better target(s) for anticancer therapy.
The EP receptors and tumorigenesis
The availability of mouse strains with genetic ablation of each EP receptor subtype and the development of selective EP antagonists (Table 1) has greatly advanced our knowledge of the pathways activated by the EP receptors and their role in malignancy.
EP1 receptor
Of the four receptors, EP 1 has the least affinity for PGE 2 (Dey et al., 2006) and so is probably activated predominantly when COX-2 is upregulated and PGE 2 synthesis is high, such as that which occurs during tumorigenesis. Some of the first studies implicating the EP 1 receptor in malignancy used EP 1 receptor knockout mice and the EP 1 receptor selective antagonists, ONO-8711 and ONO-8713 (Watanabe et al., 1999; Watanabe et al., 2000) . In a chemically induced model of colon cancer, mice lacking the EP 1 receptor were found to develop approximately 60% fewer azoxymethane-induced colonic preneoplastic lesions than wild-type mice, as well as significantly reduced colon cancer incidence. A role for these EP 1 receptor antagonists in preventing tumour development was subsequently confirmed in other cancers, including breast (Kawamori et al., 2001 ) and skin cancer (Tober et al., 2006) ( Table 1 ). The EP 3 receptors are unique in their ability to couple to multiple G proteins. Activation of Gi proteins results in the inhibition of adenylate cyclase, whereas signalling through Gs results in cAMP production. EP 3 receptors can also be coupled to G 12/13 proteins, resulting in the activation of the small G protein Rho.
The tumour-promoting role of PGE 2 -induced EP 1 receptor signalling appears to predominantly involve activation of signalling pathways mediating cell migration and invasion (Yang et al., 2010; Kim et al., 2011b; Zhang et al., 2014) . The ability to migrate and invade is a key requirement for cells to metastasize, with metastatic spread responsible for most of the mortality caused by cancer. Signalling through the EP 1 receptor by PGE 2 has also been shown to enhance integrin expression and induce the phosphorylation and activation of focal adhesion kinase (FAK) in cancer cells (Bai et al., 2013) . FAK is a non-receptor cytoplasmic tyrosine kinase that plays a key role in the regulation of cell proliferation and migration, with FAK phosphorylation shown to involve EP 1 receptor-mediated activation of the PKC/c-Src and EGFR signalling pathways (Bai et al., 2013) . Subsequent studies in hepatocellular carcinoma cells revealed that c-Src activation and transactivation of the EGFR by the EP 1 receptor also induced the expression of the transcription/translation regulatory protein Y-box binding protein 1 (YB-1) . YB-1 is overexpressed in a number of human malignancies, with expression shown to be associated with poor prognosis and disease recurrence (Kosnopfel et al., 2014) . YB-1 has been shown to regulate the expression of genes involved in epithelial-mesenchymal transition (EMT) (Kosnopfel et al., 2014) . EMT is a multi-step morphogenetic process during which epithelial cells down-regulate their epithelial properties and up-regulate mesenchymal characteristics, and is a key process in metastasis. Consistent with this, PGE 2 -induced YB-1 up-regulated the expression of Snail, a key inducer of EMT, and greatly enhanced hepatocellular carcinoma cell invasion .
PGE 2 -induced EP 1 receptor activation has also been shown to help tumours to adapt to hypoxia. Hypoxia induces COX-2 expression and increases PGE 2 levels via hypoxicinducible factor (HIF)-1, with increased levels of PGE 2 , in turn, potentiating HIF-1 transcriptional activity (Kaidi et al., 2006) . HIF-1 is a major transcription factor that activates the transcription of genes that participate in numerous cellular processes, such as the promotion of survival under conditions of low oxygen availability. Moreover, the EP 1 receptor itself was also shown to be induced in colorectal tumour cells under hypoxic conditions (Kim et al., 2011b) . This suggests that signalling through the EP 1 receptor aids in the adaptation of cancer cells to hypoxic conditions in the tumour microenvironment.
Signalling through the EP 1 receptor by PGE 2 has also been shown to induce Fas ligand (FasL) expression in cancer cells (O'Callaghan et al., 2008 (O'Callaghan et al., , 2013 , with FasL, in turn, inducing the production of PGE 2 upon binding to its receptor Fas (Zhang et al., 2009 ). Cancer cells have been shown to depend on the constitutive activity of Fas, stimulated by cancer-produced FasL, for optimal growth In contrast to the tumour-promoting activity of the EP 1 receptor in numerous tumours of varying origin, studies in breast cancer suggest that the EP 1 receptor may have an anti-metastatic function (Ma et al., 2010) , with nuclear expression of EP 1 receptors correlating with good prognostic markers (Thorat et al., 2008) . Although the reasons for these disparate findings are unclear, they may be due to the highly tissue-specific functional activities of the EP receptors. Alternatively, the nuclear EP 1 receptor may activate anti-inflammatory pathways, in contrast to the signalling pathways activated by cytoplasmic EP 1 receptor.
Finally, although most studies investigating the role of the EP 1 receptor in cancer examined the effect of EP 1 receptor antagonists on cancer initiation, targeting the EP 1 receptor using the EP 1 receptor specific antagonist ONO-8713 has also shown to be effective post cancer initiation (Watanabe et al., 2000; O'Callaghan et al., 2013) . Moreover, the EP 1 receptor is expressed in tumour cells in several cancers, including skin squamous cell carcinoma (Lee et al., 2005) , colon (Gustafsson et al., 2007) and hepatocellular cancer. Given the multiple functions ascribed to PGE 2 -EP 1 receptor signalling in cancer, this suggests that the EP 1 receptor may be a valid therapeutic target in some cancers. However, all studies demonstrating in vivo efficacy of EP 1 receptor antagonists have been performed in preclinical animal models, and it is not known whether any therapeutic benefit will be seen in human cancer. 
EP2 receptor
The majority of studies to date investigating the role of the EP 2 receptor in malignancy have relied on gene deletion studies and gene knockout mice because of the lack of a selective antagonist (Table 1) . Although AH6809 is commonly used as an EP 2 receptor antagonist, in addition to blocking the EP 2 receptor, AH6809 also acts as an EP 1 and DP 1 receptor antagonist (Abramovitz et al., 2000; Woodward et al., 2011) . However, a recently developed selective EP 2 receptor antagonist, PF-04418948, may aid in the elucidation of the role of the EP 2 receptor, complementing the gene knockout studies (af Forselles et al., 2011; Birrell and Nials, 2011) . Studies utilising EP 2 receptor knockout mice have demonstrated a role for the EP 2 receptor in malignancy, with EP 2 receptor deficient mice developing significantly less lung (Keith et al., 2006) , skin (Sung et al., 2005) and breast (Chang et al., 2005b) tumours following exposure to carcinogenic promoters. Genetic ablation of the EP 2 receptor also decreased both the size and number of intestinal polyps in adenomatous polyposis coli (APC) 1309 mice, which are genetically susceptible to intestinal polyp development (Sonoshita et al., 2001 ). Moreover, the EP 2 receptor has been shown to be expressed by tumour cells in several cancers, including colon (Gustafsson et al., 2007) , prostate (Jain et al., 2008) and breast (Chang et al., 2004) cancer.
The role of the EP 2 receptor in cancer appears most commonly ascribed to its induction of angiogenesis, with deletion of the EP 2 receptor impairing the induction of the pro-angiogenic factor, VEGF, and tumour angiogenesis (Sales et al., 2004; Chang et al., 2005a; Kamiyama et al., 2006) . In addition to the induction of VEGF upon EP 2 receptor activation (Sales et al., 2004; Chang et al., 2005a) , EP 2 receptor signalling in endothelial cells regulates endothelial cell motility and survival, further contributing to tumour angiogenesis in vivo (Kamiyama et al., 2006) . PGE 2 -induced EP 2 receptor signalling also plays an important role in suppressing the antitumour immune response (Kalinski, 2012) . Indeed, most of the immunomodulatory effects of PGE 2 on immune cells occur as a result of signalling through the EP 2 and EP 4 receptors (Nataraj et al., 2001; Kalinski, 2012) . This is probably due to the fact that signalling through both these receptors is transduced by the same Gαs stimulatory protein, and upon activation leads to an increase in the intracellular concentration of cAMP. This Table 1 Activity of EP receptor antagonists used in preclinical cancer studies EP receptor antagonists Activity EP 1 receptor: ONO-8711 Reduced formation of ACF in azoxymethane-treated mice (Watanabe et al., 1999) Delayed occurrence of PhIP c -induced breast tumours (Kawamori et al., 2001) Reduced incidence, multiplicity and volume of colon carcinomas in azoxymethane-treated rats Reduced incidence of tongue squamous cell carcinomas in 4-NQO d -treated rats (Makita et al., 2007) ONO-8713 Reduced formation of ACF in azoxymethane-treated mice (Watanabe et al., 2000) Reduced number of skin tumours induced by ultraviolet light in mice (Tober et al., 2006) Reduced breast cancer cell metastasis in syngeneic mice (Ma et al., 2006) ONO-AE3-208 Reduced breast cancer cell metastasis in syngeneic mice (Ma et al., 2006) Reduced lung cancer cell metastasis to the lung and colon cancer cell metastasis to the liver in syngeneic mice Inhibited the growth and metastasis of breast cancer cells in syngeneic mice (Xin et al., 2012) Reduced metastasis of prostate cancer cells to the bone (Xu et al., 2014) ONO-AE-227 Reduced formation of ACF in azoxymethane-treated mice and polyp number in APCmin e mice (Mutoh et al., 2002) Reduced polyp size in APC1309 f mice (Kitamura et al., 2003) a Also an antagonist of the DP 1 receptor (PGD 2 receptor) and EP 1 receptor. b Also a potent antagonist of the TP receptors (thromboxane receptors). c Chemical-induced model of breast cancer. d Chemical-induced model of squamous cell carcinoma of the tongue. e Develop multiple intestinal polyps due to a heterozygous nonsense mutation in the APC gene. f Develop multiple intestinal polyps due to the introduction of a specific mutation into the murine APC gene.
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increase in cAMP was shown to be responsible for the inhibition of T helper (T H )1 cells and the associated reduction in IL-2 and IFNγ (Betz and Fox, 1991; Harris et al., 2002) , which is important given that CD4 + T H cells represent a key effector arm of the adaptive immune system required for cancer control. PGE 2 also inhibits, in an EP 2 and EP 4 receptor-mediated fashion, the activity of NK cells and cytotoxic T cells (CTL) (Martinet et al., 2010; Holt et al., 2012) , two cell types that can also form part of the antitumour immune response. In addition to directly suppressing the activity of immune cells, signalling through the EP 2 and EP 4 receptors promotes the development of Treg cells (Sharma et al., 2005) . Treg cells are potent inhibitors of the immune system, suppressing the activity of numerous immune cells, including dendritic cells (DCs) (Lakshmi Narendra et al., 2013) . DCs play a central role in the initiation of the tumour-specific immune response, with the presence of DCs in tumours correlating with improved prognosis (Gulubova et al., 2012) . Signalling through the EP 2 (and EP 4 ) receptors not only blocked the activity of DCs through the induction of Treg cells but also blocked their generation from monocytes, resulting instead in the development of the immunosuppressive MDSCs from monocytes (Sinha et al., 2007; Obermajer and Kalinski, 2012; De Keijzer et al., 2013) . Despite these studies demonstrating an immunosuppressive function for the EP 2 (and EP 4 ) receptors, PGE 2 is also a potent pro-inflammatory factor (Yao et al., 2009) . In contrast to its inhibitory effect on the generation of DCs, PGE 2 promotes the maturation of immature DCs and enhances their T cell stimulatory capacity (De Keijzer et al., 2013) . Moreover, PGE 2 can either inhibit (Betz and Fox, 1991; Harris et al., 2002) or promote (Yao et al., 2009 ) T H 1 cell differentiation, with promotion requiring a strong T cell receptor (TCR) activation signal, together with a low concentration of PGE 2 . Whether the pro-inflammatory or anti-inflammatory effects of PGE 2 prevail appears to depend to a large degree on the presence and type of activated cells, their maturation status, the concentration of PGE 2 and on the local balance of proinflammatory and anti-inflammatory factors present in the microenvironment (Sreeramkumar et al., 2012) . Thus, in the tumour microenvironment, it is likely that the antiinflammatory and pro-tumorigenic function of PGE 2 prevails because of the low level of chronic inflammation present, coupled with the immunosuppressive microenvironment.
In addition to being associated with angiogenesis and immune suppression in malignancy, a recent study showed that EP 2 receptor activation by PGE 2 markedly enhanced hepatocellular carcinoma cell invasion and migration ability by upregulating the expression level of Snail, a key inducer of EMT . The EP 2 receptor has also been linked to metastasis in breast cancer, in part through its ability to alter the response of cells to TGF-β (Tian and Schiemann, 2010) . TGF-β plays an essential role in maintaining tissue homeostasis by inducing cell cycle arrest, differentiation and apoptosis. However, during tumorigenesis, genetic and epigenetic events convert TGF-β from a tumour suppressor to a promoter of cell growth, invasion and metastasis (Siegel and Massague, 2003) . The altered response to TGF-β was because of the suppression of TGF-β-induced Smad2/3 nuclear localisation and signalling by PGE 2 , thus uncoupling TGF-β from activating Smad3, with TGF-β instead stimulating breast cancer cell invasion and metastasis (Tian and Schiemann, 2010) .
EP3 receptor
The role of the EP 3 receptor in tumorigenesis is unclear, with studies reporting conflicting effects on tumorigenesis following targeting of the EP 3 receptor. Genetic deletion of the EP 3 receptor had no effect on colon tumour formation in APC Δ716 mice, which spontaneously develop numerous polyps in the intestinal tract (Sonoshita et al., 2001) . Similarly, treatment of breast cancer cells with the EP 3 antagonist ONO-AE3-240 had no effect on breast cancer metastasis (Ma et al., 2006) ( Table 1 ).In contrast, azoxymethane-induced colon cancer development was enhanced in EP 3 receptor knockout mice compared with wild-type mice, suggesting an antitumorigenic function for the receptor in this model (Shoji et al., 2004) . In the skin, EP 3 receptor deficiency either had no effect (Sung et al., 2005; Rundhaug et al., 2011) or was shown to contribute to squamous cell carcinoma (SCC) development, but not progression (Shoji et al., 2005) . Consistent with the EP 3 receptor not playing an important role in tumorigenesis, EP 3 receptor expression has been shown to be down-regulated in colonic tumour cells relative to normal mucosa epithelial cells (Shoji et al., 2004) . Similar findings of a down-regulation of the EP 3 receptor in cancer was seen in the skin with regards to SCC (Lee et al., 2005) and in breast cancer (Chang et al., 2004) .
Some studies suggest an indirect pro-tumorigenic function for the EP 3 receptor, whereby signalling through host stromal EP 3 receptor plays a role in tumour development by promoting angiogenesis and lymphangiogenesis. The growth and metastasis of implanted tumours was shown to be suppressed in EP 3 receptor knockout mice, with suppression associated with a reduction in VEGF and matrix metalloproteinase-9 (MMP9) expression in the stroma, concomitant with a reduction in tumour-associated angiogenesis (Amano et al., 2003; Amano et al., 2009; Ogawa et al., 2009) . Consistent with this, overexpression of the EP 3 receptor in HEK cells increased expression of VEGF and its receptor VEGFR1 (Taniguchi et al., 2008) . EP 3 receptor signalling by host cells was also shown to play an important role in tumour-associated lymphangiogenesis (Kubo et al., 2010) . The expression of a potent pro-lymphangiogenic growth factor, VEGF-C, and its receptor, VEGFR3, in the stromal compartment of the tumour tissues was also found to be significantly reduced in EP 3 receptor knockout mice, as was expression of podoplanin, a marker for lymphatic endothelial cells (Kubo et al., 2010) .
Such discrepancies may be due to differences in the expression of the isoforms of the EP 3 receptor. As the EP 3 receptor is capable of stimulating or inhibiting cAMP (by stimulating or inhibiting adenylate cyclase), as well as stimulating Ca 2+ mobilization, differences in isoform expression may account for the differing responses seen in these tumours. Alternatively, the function of the EP 3 receptor in tumorigenesis may be determined by its cellular location in the tumour microenvironment, with stromal, and not tumour cell, expression of the EP 3 receptor important in promoting tumorigenesis. The existence of these isoforms, as well as the differing outcomes seen following suppression of EP 3 receptor signalling suggest that the EP 3 receptor is unlikely to be a promising target for anticancer therapy.
EP4 receptor
Of the four EP receptors, the EP 4 receptor is probably the one that is best characterized in terms of its involvement in cancer. PGE 2 -induced EP 4 receptor activation has been implicated in a number of diverse cellular processes. As outlined earlier (see EP 2 receptor), signalling through the EP 4 receptor by PGE 2 promotes the development of a pro-tumorigenic immune response, inducing the development of Treg cells (Sharma et al., 2005) and MDSCs (Sinha et al., 2007; Obermajer and Kalinski, 2012; De Keijzer et al., 2013) , as well as suppressing NK and CTL activity (Martinet et al., 2010; Holt et al., 2012) . The EP 4 receptor can also play a role in tumour cell migration and metastasis (Buchanan et al., 2006; Xia et al., 2014) . Several different signalling pathways have been shown to mediate this effect. For instance, PGE 2 was shown to significantly upregulate c-Myc expression in hepatocellular carcinoma cells through the activation of the CREB transcription factor ( Figure 2C ), thus promoting cell growth and invasion . Alternatively, in colon cancer cells, activation of the EP 4 receptor increased cell proliferation and VEGF production, with mTORC1 acting as a signalling intermediary (Dufour et al., 2014) . EP 4 receptor activation was also shown to promote the migration and metastasis of colon cancer cells via the formation of an EP 4 /β-arrestin/c-Src signalling complex that transactivated the EGFR, resulting in the downstream activation of the PI3K/Akt signalling pathway (Figure 3) (Buchanan et al., 2006; Vo et al., 2013) . Activation of the PI3K/Akt pathway can also lead to upregulation of Snail expression (Lau and Leung, 2012) , important for EMT. Consistent with this, suppression of the EP 4 receptor blocked PGE 2 -induced Snail expression (Kim et al., 2011a) . PGE 2 , signalling through the EP 4 receptor, has recently been shown to also play a role in promoting aberrant DNA methylation in colon tumours (Xia et al., 2012) . Aberrant DNA methylation is considered to be one of the major mechanisms by which key genes involved in the tumorigenic process, such as tumour-suppressor genes and DNA repair genes, are silenced. Signalling by PGE 2 through the EP 4 receptor induced the expression of two DNA methytransferases, DNMT1 and DNMT3B, in colon cancer cells (Xia et al., 2012) . Moreover, treatment of APC min/+ mice with PGE 2 induced the expression of DNMT1 and DNMT3B in colonic tumours and accelerated the growth of intestinal adenomas, whereas treatment with a de-methylating agent reversed the effect of PGE 2 on intestinal growth (Xia et al., 2012) . In cancer, gene silencing through methylation occurs at least as frequently as mutations or deletions. Thus, PGE 2 , through its ability to contribute to the dysregulated hypermethylation seen in numerous cancers, may help to drive the tumorigenic process. Metabolic changes are an emerging hallmark of cancer (Hanahan and Weinberg, 2011) required to meet the energetic and biosynthetic demands of growing tumours. Although cancer cells have traditionally been thought to rely on the glycolytic pathway to generate ATP, recent studies suggest that cancer cells can shift to the fatty acid oxidation pathway as an alternative energy source. PGE 2 was recently shown to induce the expression of NR4A2 in colon cancer cells via the EP 4 receptor, with NR4A2 in turn, increasing fatty acid oxidation by inducing the expression of multiple proteins in the fatty acid oxidation pathway (Holla et al., 2006 (Holla et al., , 2011 . Enhanced expression of NR4A2 is also associated with increased resistance to chemotherapy and enhanced tumour cell survival (Han et al., 2013) . Thus, PGE 2 , acting through the EP 4 receptor, may promote tumorigenesis by acting as a regulator of the adaptive shift in tumours to energy utilization via fatty acid oxidation.
Consistent with the many roles identified for the EP 4 receptor in tumorigenesis, blocking the EP 4 receptor, using either EP 4 knockout mice and/or a selective EP 4 antagonist, was shown to suppress tumour development and progression in numerous tumour types. Several EP 4 receptor specific antagonists are available, including ONO-AE3-208, ONO-AE2-227 and AH23848 (Table 1) , and they were shown to suppress tumour cell migration, invasion and metastasis in colon (Mutoh et al., 2002; Chell et al., 2006; Yang et al., 2006) , breast (Ma et al., 2006; Xin et al., 2012) and prostate (Xu et al., 2014) cancer. EP 4 receptor knockout mice also showed a reduction in the formation of azoxymethane-induced colon aberrant crypt foci (ACF), with ONO-AE2-227 administered in the diet at the time of azoxymethane administration also capable of reducing the formation of ACF (Mutoh et al., 2002) . Consistent with a role for the EP 4 receptor in tumorigenesis, expression of the EP 4 receptor was up-regulated in numerous cancers, including colon (Chell et al., 2006) , breast (Kundu et al., 2014) and prostate (Jain et al., 2008) cancer.
Conclusions
Extensive preclinical and epidemiological studies support the targeting of the COX pathway for the prevention and treatment of malignancy. However, the use of COXibs over prolonged periods of time is not recommended because of the significant gastrointestinal and renal toxicities associated with them. As PGE 2 mediates most, if not all, of the carcinogenic effects of COX-2 overexpression, extensive efforts have focused on identifying the signalling pathways activated by the EP receptors, with the hope that targeting EP receptor signalling may circumvent the toxic effects associated with COX inhibition, whilst simultaneously retaining the anticancer properties. EP receptor antagonists, in particular those targeting the EP 1 , EP 2 and EP 4 receptors, have been used successfully in preclinical models to suppress the development and growth of tumours. However, whether they will prove effective, and less toxic, in clinical studies is unknown. One limitation may be the effectiveness of these antagonists as compared with NSAIDs. Whilst COXibs inhibit all prostaglandins downstream of the COX, EP receptor antagonists target only one pathway. Thus, more than one antagonist may be required to suppress and/or treat malignant disease. For instance, the use of both EP 1 and EP 4 antagonists were shown to yield additive effects on colon tumour development and growth, compared with treatment with either antagonist alone, in a preclinical model (Kitamura et al., 2003) . Moreover, given the extensive crosstalk between the EP receptors and the EGF signalling pathways, combined targeting of individual EP receptors and the EGFR pathway may yield improved chemotherapeutic benefits and improved clinical outcome in cancer. Whether combinations of specific antagonists represent a more efficient therapeutic option is currently unclear. In conclusion, whilst extensive studies have elucidated many of the signalling pathways activated by the EP receptors, future studies are required to determine whether the EP receptors represent possible therapeutic targets in malignancy.
